Moderna Seeks $2.8 Million in Legal Fees Following Patent Dispute Over COVID-19 Vaccine

Moderna is requesting approximately $2.8 million in legal fees from a Delaware federal court following a patent lawsuit initiated by Alnylam Pharmaceuticals. The dispute centers on Moderna’s coronavirus vaccine, with Moderna claiming that Alnylam pursued “frivolous” legal actions which allegedly squandered legal resources. The case reflects ongoing patent litigation within the pharmaceutical industry, particularly as companies navigate the complex landscape of coronavirus-related intellectual property rights. Additional details about the case can be found in the original report.